Evidence map›Paper›PMID 23678107›Full record

ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2013

Specific acetylation of p53 by HDAC inhibition prevents DNA damage-induced apoptosis in neurons.

Camille Brochier, Gretel Dennis, Mark A Rivieccio, Kathryn McLaughlin, Giovanni Coppola, Rajiv R Ratan, Brett Langley

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Molecules (Basel, Switzerland) · 2024
    Article
  7. Review
  8. Rbbp4 loss disrupts neural progenitor cell cycle regulation independent of Rb and leads to Tp53 acetylation and apoptosis.Developmental dynamics : an official publication of the American Association of Anatomists · 2022
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Camille BrochierBurke Medical Research Institute, White Plains, New York 10605, USA.
Gretel Dennis
Mark A Rivieccio
Kathryn McLaughlin
Giovanni Coppola
Rajiv R Ratan
Brett Langley
Cornell University · USBurke Medical Research Institute · USUniversity of California, Los Angeles · US

Funding

Stem CellsP30HD004612 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BOOKHEIMER, SUSAN Y · 1985 to 2014
$19.5M
NICHD NIH HHS P30 HD004612
6 · The paper itself

Abstract

Histone deacetylase (HDAC) inhibitors have been used to promote neuronal survival and ameliorate neurological dysfunction in a host of neurodegenerative disease models. The precise molecular mechanisms whereby HDAC inhibitors prevent neuronal death are currently the focus of intensive research. Here we demonstrate that HDAC inhibition prevents DNA damage-induced neurodegeneration by modifying the acetylation pattern of the tumor suppressor p53, which decreases its DNA-binding and transcriptional activation of target genes. Specifically, we identify that acetylation at K382 and K381 prevents p53 from associating with the pro-apoptotic PUMA gene promoter, activating transcription, and inducing apoptosis in mouse primary cortical neurons. Paradoxically, acetylation of p53 at the same lysines in various cancer cell lines leads to the induction of PUMA expression and death. Together, our data provide a molecular understanding of the specific outcomes of HDAC inhibition and suggest that strategies aimed at enhancing p53 acetylation at K381 and K382 might be therapeutically viable for capturing the beneficial effects in the CNS, without compromising tumor suppression.

Indexed as

AcetylationAnalysis of VarianceAnimalsApoptosisApoptosis Regulatory ProteinsBrainCells, CulturedChromatin ImmunoprecipitationCyclin-Dependent Kinase Inhibitor p21DNA DamageElectroporationEmbryo, MammalianEnzyme InhibitorsFemaleHistone DeacetylasesHumansApoptosis Regulatory ProteinsCyclin-Dependent Kinase Inhibitor p21Enzyme InhibitorsHistone DeacetylasesLysinePUMA protein, mouseRNA, Small InterferingTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID23678107
PMCPMC6618832
OpenAlexW2119391432

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.